Products used in biosurgery are usually made of semi-synthetic, synthetic, or natural materials that aid in tissue healing and sealing surgical incisions. For a variety of surgical situations, they regulate blood loss. Neurological, orthopedic, and cardiovascular procedures are well-known surgeries for which biosurgery products are helpful.
The market worth of biosurgery in 2021 was USD 15.93 billion, and it will be worth USD 26.25 billion by 2030, growing at a 5.7% CAGR during the forecast period.
Furthermore, people with diabetes benefit from biosurgery therapy. During the projected period, rising spinal cord injuries and diabetes cases will boost revenue growth in the biosurgery market. Other significant factors influencing market expansion include rising demand for less invasive surgical procedures and a rapidly aging population with chronic diseases and disorders.
The market for biosurgery is rising quickly due to the rising number of accidents and operations that cause significant blood loss. High demand for items used in biosurgery is ascribed to a number of causes, including the existence of new players in the market and the use of contemporary marketing endorsements. The biosurgery market will expand due to better reimbursement rules and increased consumer demand for the goods. Market revenue growth is being driven by technological developments in the research and development of several products that are extremely effective, as well as an increase in surgeries because there is a huge population suffering from various types of illnesses.
The market for biosurgery commands high prices since existing competitors are engaged in intense competition. The target patient population in growing countries prefers the conventional product during surgeries due to the high cost and hospital reimbursement scenario for these goods, restraining the market growth.
Given the rising healthcare expenses in affluent nations like France, Germany, the United States, and the United Kingdom, growth in medical tourism may present the substantial potential for emerging nations like India, China, and Malaysia.
By product type, the surgical sealants market segment ruled the biosurgery market in 2021. The market for surgical sealants and adhesives has grown as a result of the incidence of back pain and sports-related injuries. Additionally, biomaterials like fibrin and collagen-based adhesives are well-tolerated by the body’s immune system. Strong adhesive qualities are another benefit of synthetic and artificial sealants, which may be needed in damage scenarios involving “awkward locations.”
The general surgery segment ruled the global biosurgery market in terms of surgery. This is because a general surgeon is capable of a variety of procedures. The treatment of hernias, hemorrhoids, colonoscopies, breast surgery, and even the removal of the appendix or gall bladder can all be supported by a general surgeon.
In terms of end-user in 2021, the hospital sector ruled the biosurgery market. In contrast to other end-use segments, hospitals do an increasing proportion of general and gynecological surgery. The development of modern biosurgery treatment modalities and the growth of multispecialty institutions have boosted the biosurgery market.
With a share of roughly 32%, North America ruled the total market. The largest market share is due to the rising incidence of obesity, the desire for complex surgical procedures, the frequency of orthopedic surgery, the amount of money spent on healthcare, and public awareness of the benefits. Advanced healthcare infrastructure and state-of-the-art technology and treatments are further factors encouraging market progress in the region.
Due to the rising elderly population who are more susceptible to various ailments, Europe will hold the second-largest market share over the projection period. The demand for biosurgery in the region is also growing due to advancements in the healthcare industry and the use of cutting-edge medical technologies.
- Medtronic Plc
- Becton, Dickinson & Co.
- Johnson & Johnson
- Baxter International Inc.
- B. Braun Melsungen AG
- CSL Ltd.
- Hemostasis L.L.C.
- Stryker Corp.
- Integra Lifesciences Holdings Corp.
- Pfizer Inc.
- Kuros Biosciences AG
- Orthofix Medical Inc.
- Cyrolife Inc.
- Zimmer Biomet
- Smiths & Nephew Plc.
- Genzyme biosurgery
The market worth of biosurgery in 2021 was USD 15.93 billion, and it will be worth USD 26.25 billion by 2030, growing at a 5.7% CAGR during the forecast period. Due to an aging population, rising healthcare costs, and an increase in sports-related injuries, the global biosurgery market is expanding significantly. The market is also expanding due to the rising rate of chronic disorders like diabetes mellitus, cancer, cardiovascular disease, infectious diseases, autoimmune diseases, and nephrological diseases.